UBS analyst Danielle Antalffy keeps a Buy rating on Inspire Medical with a $265 price target after hosting meetings with management. The firm walked away reinforced in its belief that the company’s near-to-mid term growth trajectory “remains very much intact” despite persistent fears around impact from GLP-1s that has pressured the stock. The firm believes Inspire can sustainably grow 20% over the next few years even if there’s potential disruption in the existing treatment paradigm for obstructive sleep apnea patients.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on INSP:
- Inspire Medical reports Q3 adjusted EPS 17c vs. 41c last year
- ‘Fundamentals Appear Positive’: KeyBanc Suggests 2 MedTech Stocks With up to ~40% Upside
- Inspire Medical’s New Regulation Risk – A Cause for Worry?
- Inspire Medical price target raised to $280 from $265 at Truist
- Inspire Medical price target raised to $270 from $240 at Lake Street
